Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial ...

10x Genomics, Inc. (NASDAQ:TXG) ... The company had successful launches of its Visium instrument in late 2022 and its new Xenium platform in early 2023. In addition, ...

Combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection enables a deeper, more holistic understanding of tissue organization PLEASANTON, Calif., May 24, ...

Combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection enables a deeper, more holistic understanding of tissue organization PLEASANTON, Calif., May ...

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables ...

PARIS, Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium ...

PLEASANTON, Calif. - 10x Genomics, Inc. (NASDAQ: NASDAQ:TXG), a company specializing in single cell and spatial biology, has launched Visium HD Spatial Gene Expression, a new product designed to ...

French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to ...

PARIS and PLEASANTON, Calif., Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that ...